Catalyst Financial Partners LLC Buys 52 Shares of Danaher Co. (NYSE:DHR)

Catalyst Financial Partners LLC lifted its stake in Danaher Co. (NYSE:DHR) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,243 shares of the conglomerate’s stock after purchasing an additional 52 shares during the period. Catalyst Financial Partners LLC’s holdings in Danaher were worth $750,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. BKM Wealth Management LLC acquired a new stake in shares of Danaher in the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. acquired a new stake in Danaher in the fourth quarter worth about $29,000. OFI Invest Asset Management bought a new stake in Danaher during the 3rd quarter worth about $30,000. Rakuten Securities Inc. acquired a new position in Danaher during the 4th quarter valued at about $36,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Danaher during the 4th quarter worth approximately $41,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.8 %

NYSE:DHR traded up $1.93 during trading hours on Thursday, reaching $251.48. 1,604,343 shares of the stock were exchanged, compared to its average volume of 2,716,949. The stock has a market cap of $186.27 billion, a PE ratio of 42.62, a PEG ratio of 3.82 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00. The firm has a 50 day moving average of $248.15 and a 200 day moving average of $233.30. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the company posted $2.36 earnings per share. The firm’s revenue was down 2.6% on a year-over-year basis. On average, equities analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling at Danaher

In other news, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold a total of 103,984 shares of company stock worth $25,997,094 over the last ninety days. 10.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. TD Cowen increased their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Citigroup raised their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Robert W. Baird upped their price target on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Raymond James increased their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $267.31.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.